La Jolla Pharmaceutical Company (LJPC) Stock Ratings


View Stock Quote:

Login Required

You must login before you can rate this stock.

Login Now

Community Rating:


Not Rated

No Current Ratings
View All-Time Ratings

Do the wall street analysts agree?

Consensus Recommendation:

View detailed analyst research

Other Member Ratings

View Most Rated Stocks

Member Call Date Rated Timeframe Start Price End Price Stock Gain/Loss Score Status
Netteligent Netteligent 06/16/2019 1 month $9.71 $9.24 -4.84% 4 Ended
Comments: High Risk. Speculation. Slow market. Stock Overpriced
laurvp laurvp 12/07/2015 1 month $29.17 $22.91 -21.46% 21 Ended
Comments:
alicetta alicetta 11/04/2014 1 Year $11.07 $28.75 +159.71% 159 Ended
Comments:
Joward Joward 02/26/2014 1 Year $9.10 $20.19 +121.87% 121 Ended
Comments:
villanueva villanueva 02/26/2014 1 Year $9.14 $20.19 +120.9% 120 Ended
Comments:
markrefuerzo markrefuerzo 02/26/2014 1 Year $8.95 $20.19 +125.59% 125 Ended
Comments:
InvestorsXpress InvestorsXpress 02/26/2014 3 months $7.60 $7.58 -0.26% -1 Ended
Comments: 70% chance phase two efficacy should be met!
fdr2010 fdr2010 03/01/2010 3 months N/A Ended
Comments:
JCdeR JCdeR 02/28/2010 3 months N/A Ended
Comments: LJPC is going ....
MoMoney_1 MoMoney_1 02/09/2010 3 months N/A Ended
Comments:
CeeDee CeeDee 02/03/2010 3 months N/A Ended
Comments: ...will however come at least back to 0.2
tigre173 tigre173 12/17/2009 3 months N/A Ended
Comments:
Chadi A. Chadi A. 12/12/2009 3 months N/A Ended
Comments: The best ..The new drug it will be approved
musicmag musicmag 12/09/2009 3 months N/A Ended
Comments:
bruno_1 bruno_1 12/08/2009 3 months N/A Ended
Comments: popup for tomorrow
moe1 moe1 12/07/2009 3 months N/A Ended
Comments:

Neither NASDAQ, Inc. nor any of its affiliates (collectively "NASDAQ") makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Investment related advice and comments are solely those of the individuals who publish them and do not in any way represent the opinions of NASDAQ. Investors should undertake their own due diligence and carefully evaluate companies before investing.